A top Trump administration official highlighted a potential flaw in the president's most-favored nation drug pricing plan, suggesting it could inadvertently raise prices abroad and be ineffective by the time new drugs launch internationally. Gilead Sciences is acquiring Ouro Medicines for up to $2.18 billion to expand its autoimmune disease portfolio through a collaboration with Galapagos, emphasizing strategic acquisitions in the pharmaceutical industry. Content creators should focus on detailed analysis of policy implications and corporate strategies in healthcare news to provide valuable insights.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
21
Comments
Ali NematiWritten by Ali
